8247 — BioSino Bio-technology and Science Balance Sheet
0.000.00%
- HK$111.42m
- HK$220.91m
- CNY263.07m
- 17
- 66
- 59
- 44
Annual balance sheet for BioSino Bio-technology and Science, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 45.5 | 44.5 | 77.3 | 63.4 | 68.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 242 | 257 | 247 | 211 | 153 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 387 | 408 | 397 | 350 | 285 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 130 | 107 | 85.2 | 83.7 | 74.6 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 625 | 608 | 603 | 563 | 477 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 379 | 389 | 346 | 321 | 293 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 447 | 432 | 397 | 353 | 310 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 177 | 176 | 206 | 210 | 168 |
| Total Liabilities & Shareholders' Equity | 625 | 608 | 603 | 563 | 477 |
| Total Common Shares Outstanding |